Innovative new mass spectrometer for rapid, robust, and detailed data on all components in complex mixtures

沃里克大学衍生出来的Verdel仪器有限公司正在开发一项创新的专利技术，该技术将使科学家能够同时获得数千种分子化合物的详细结构信息，这种新技术被称为二维质谱（2DMS）。2DMS允许用户同时对大范围的分子进行片段化，同时跟踪哪些片段来自哪些前体分子。实际上，2DMS同时对所有化合物并行地进行这些碎片化研究，而不是一次对一种化合物进行连续的碎片化研究，这大大加快了实验的速度。虽然该技术的第一个版本是在非常先进的质谱仪上开发的，并且只在学术界使用，但Verdel开发了一种适用于常规台式质谱仪的方法，该方法将足够快，可以在几秒钟内提供这些全面的碎片数据集，因此与色谱技术兼容。我们的新技术将是病毒检测、表征和追踪的理想选择，这是当前COVID危机的关键需求。化学、临床、生物技术和制药行业广泛使用质谱法来鉴定样品或配方中的分子，检测污染物，并定量重要化合物。新的2DMS技术将大大提高这些分析的数据质量和速度。我们有两个原型仪器是通过修改现有的商用质谱仪制成的，因此没有针对新演示的2DMS技术进行设计和优化。因此，该项目将在我们现有原型的基础上开发一种全新的质谱仪。在短期内，Verdel将为客户提供样品分析服务，以发展技术并了解市场。在有需要的地方，Verdel将出售经过修改以启用2DMS的现有仪器。该商业计划将开发2DMS技术的市场，确定我们技术的早期采用者，他们将是未来的好客户，开发早期收入流，并继续发展我们的知识产权地位，以提高业务的商业价值。这种商业方法将与这个拟议的工业研究项目相结合，为推出正在开发的2DMS仪器做好准备。此外，这种方法将使我们能够验证2018年ICURe队列的市场分析，并更深入地了解2DMS在各种使用应用中对客户的价值，从而开发我们的定价模型。

Verdel Instruments Ltd, a University of Warwick spin out, is developing an innovative and patented technology which will allow scientists to obtain detailed structural information for thousands of molecular compounds simultaneously using the new technique called two-dimensional mass spectrometry (2DMS). 2DMS allows a user to fragment a wide range of molecules simultaneously and, at the same time, keep track of which fragments come from which precursor molecules. Effectively, 2DMS performs these fragmentation studies in parallel on all compounds at once, rather than serially one compound at a time, which greatly speeds up the experiment. While the first versions of the technology were developed on very advanced mass spectrometers and have only been used in academia, Verdel has developed an approach which is suitable for routine bench-top mass spectrometers which will be fast enough to provide these comprehensive fragmentation datasets in a few seconds and thus are compatible with chromatographic techniques. Our new technology will be ideal for viral detection, characterisation, and tracing, a critical need in the current COVID crisis.The chemical, clinical, biotechnology, and pharmaceutical industries use mass spectrometry extensively to identify the molecules in their samples or formulations, detect contaminants, and to quantify important compounds. The new 2DMS technology will greatly improve the data quality and speed for those analyses. We have two prototype instruments made by modifying existing commercial mass spectrometers and so are not designed and optimised for the newly demonstrated 2DMS technique. Thus, the project will develop an entirely new mass spectrometer based on our existing prototypes.In the short term, Verdel will offer a sample analysis service to customers to develop the technique and learn about the market. Where there is a need, Verdel will sell existing instruments modified to enable 2DMS. This business plan will develop the market for 2DMS technologies, identify early-adopters of our technology who will be good future customers, develop an early stage income stream, and continue to develop our intellectual property position to improve the commercial value of the business. This business approach will combine with this proposed industrial research project, preparing the market for the launch of the 2DMS instrument being developed. Furthermore, this approach will allow us to validate the market analysis from the 2018 ICURe cohort and more deeply understand the value of 2DMS to customers in various usage applications thus developing our pricing model.